Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBV regimen in first salvage Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma
2014-005382-79Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2021
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin and bendamustine in Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: overall objective response rate. Started Sep 2021; status: terminated.
02
Drugs
brentuximab vedotinbendamustine
03
Conditions
Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2014-005382-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005382-79.